# CAC Score and CCTA Risk Stratification Tables
# Format: exam_name,risk_type,level_0,level_1,level_2,level_3,level_4,level_5,unit,conversion

# CAC Score - Agatston Score (Linear Risk)
CAC_AGATSTON,linear,>1000,401-1000,101-400,11-100,1-10,0,AU,Absoluto (sem conversão)

# CAC Percentile (Age/Sex/Race Specific) (Linear Risk)
CAC_PERCENTILE,linear,≥90th,75-89th,50-74th,25-49th,<25th,,percentile,Baseado MESA study

# CAC Progression Annual (Linear Risk)
CAC_PROGRESSION,linear,>30%,20-30%,15-20%,<15%,,,percent_per_year,Mudança percentual anual

# CAC Density (Linear Risk)
CAC_DENSITY,linear,Baixa (<130 HU),Mista,Moderada (130-400 HU),Alta (>400 HU),,,HU,Hounsfield Units

# CCTA - CAD-RADS (Linear Risk)
CCTA_CADRADS,linear,5 (100%),4B (LM/3v),4A (70-99%),3 (50-69%),2 (25-49%),1 (1-24%),0 (0%),stenosis_percent,Porcentagem de estenose

# Plaque Burden Score (Linear Risk)
PLAQUE_BURDEN,linear,P4 (Extenso),P3 (Mod-Severo),P2 (Moderado),P1 (Leve),P0 (Ausente),,categorical,Baseado SIS/CAC/visual

# High-Risk Plaque Features Count (Linear Risk)
HRP_FEATURES,linear,4 features,3 features,2 features,1 feature,0 features,,count,Número de características alto risco

# Advanced Lipids - ApoB (Linear Risk)
APOB,linear,>130,100-130,80-99,65-79,50-64,<50,mg/dL,1 mg/dL = 0.01 g/L

# Advanced Lipids - Lp(a) (Linear Risk)
LPA,linear,>150,100-150,50-99,30-49,<30,,mg/dL,1 mg/dL = 2.5 nmol/L

# Advanced Lipids - LDL-P (Linear Risk)
LDLP,linear,>2000,1600-2000,1300-1599,1000-1299,<1000,,nmol/L,Partículas LDL por litro

# Inflammatory - hs-CRP (Linear Risk)
HSCRP,linear,>10,3-10,1-3,0.5-1,<0.5,,mg/L,1 mg/L = 1000 µg/dL

# Inflammatory - Lp-PLA2 (Linear Risk)
LPPLA2,linear,>235,200-235,175-199,150-174,<150,,ng/mL,Marcador inflamação vascular

# Detailed Risk Level Descriptions
# exam_name,level,label,annual_event_rate,5year_event_free,recommendations

CAC_AGATSTON,5,Risco Muito Baixo,0.11%,~95%,Sem estatina; reassess 5-15 anos
CAC_AGATSTON,4,Risco Baixo,0.3%,~93%,Considerar estatina se idade >55 anos
CAC_AGATSTON,3,Risco Moderado,0.7%,~89%,Estatina recomendada
CAC_AGATSTON,2,Risco Moderado-Alto,1.4%,~83%,Estatina + ezetimiba
CAC_AGATSTON,1,Risco Alto,2.1%,~77%,Terapia intensiva
CAC_AGATSTON,0,Risco Muito Alto,3-4%,<70%,Terapia máxima + cardiologia

CCTA_CADRADS,6,Sem Placa (0%),~1%,95.2%,Lifestyle apenas
CCTA_CADRADS,5,Estenose Mínima (1-24%),~1.4%,92.9%,Prevenção primária agressiva
CCTA_CADRADS,4,Estenose Leve (25-49%),~2.2%,88.7%,Prevenção secundária
CCTA_CADRADS,3,Estenose Moderada (50-69%),~3%,84.5%,Teste de isquemia (stress/FFR-CT)
CCTA_CADRADS,2,Estenose Severa 1-2v (70-99%),~4.6%,76.7%,Angiografia invasiva provável
CCTA_CADRADS,1,Estenose Severa 3v/LM,~4.6%,76.7%,Angiografia invasiva urgente
CCTA_CADRADS,0,Oclusão Total (100%),~6.2%,69.3%,Angiografia invasiva + revascularização

HRP_FEATURES,4,Sem Características Alto Risco,Baseline,Baseline,Risco basal conforme CAD-RADS
HRP_FEATURES,3,1 Característica Alto Risco,+30%,Baseline,Risco moderadamente aumentado
HRP_FEATURES,2,2 Características Alto Risco,+100%,Baseline,Risco alto
HRP_FEATURES,1,3 Características Alto Risco,+150%,Baseline,Risco muito alto
HRP_FEATURES,0,4 Características Alto Risco,+250%,Baseline,Risco extremo (HR 2.5+ para MACE)

# Warranty Period Matrix (CAC=0)
# age_group,gender,diabetes,lpa_high,warranty_years

<45,M,No,No,10-15
<45,M,No,Yes,5-7
<45,M,Yes,No,3-5
<45,M,Yes,Yes,3-5
45-55,M,No,No,7-10
45-55,M,No,Yes,5
45-55,M,Yes,No,3-5
45-55,M,Yes,Yes,3
>55,M,No,No,5-7
>55,M,No,Yes,3-5
>55,M,Yes,No,3
>55,M,Yes,Yes,3
<55,F,No,No,10-15
<55,F,No,Yes,7-10
<55,F,Yes,No,5-7
<55,F,Yes,Yes,3-5
>55,F,No,No,7-10
>55,F,No,Yes,5-7
>55,F,Yes,No,3-5
>55,F,Yes,Yes,3

# Combined Risk Stratification (CAC + ApoB + Lp(a))
# cac_category,apob_category,lpa_category,risk_10year,therapy_intensity

0,<80,<50,<5%,Lifestyle only
0,>80,<50,5-10%,Consider statin
0,Any,>100,10-15%,Statin + future anti-Lp(a)
1-99,>80,>50,15-20%,Statin + ezetimibe
100-400,>80,>50,20-30%,Statin + ezetimibe + PCSK9i
>400,Any,Any,>30%,Maximal therapy + cardiology

# CAC Progression Risk Categories
# annual_change_percent,risk_category,action

<15,Normal,Continue current therapy
15-20,Typical,Optimize lifestyle + medications
20-30,Accelerated,Intensive intervention required
>30,Very Accelerated,Urgent cardiology referral

# High-Risk Plaque Features Definitions
# feature_name,definition,hounsfield_threshold,clinical_significance

Positive Remodeling,Vessel area >10% larger than reference,N/A,Vulnerable plaque expansion
Low-Attenuation Plaque,Low density plaque,<30 HU,Lipid-rich highly vulnerable
Napkin-Ring Sign,Hypodense core + hyperdense ring,Variable,Necrotic core thin cap fibroatheroma
Spotty Calcification,Calcification <3mm,>130 HU,Early unstable calcification

# Functional Medicine Supplement Protocol (CAC ≥400)
# supplement,dosage,evidence_level,study_reference

Vitamin K2 (MK-7),720 µg/day,High,AVADEC Trial 2024
Vitamin D3,25 µg/day (1000 IU),High,AVADEC Trial 2024
Magnesium,400-600 mg/day,Moderate,Multiple observational
Omega-3 EPA/DHA,2-4 g/day,High,Meta-analyses
CoQ10,100-200 mg/day,Moderate,Statin-induced depletion
Bergamot,500-1000 mg/day,Moderate,Lipid optimization

# Lifestyle Intervention Targets
# intervention_type,target,expected_benefit

Diet Mediterranean,85% adherence,30% event reduction
Diet Low-Carb,<100g carbs/day,25-30% TG reduction
Exercise Aerobic,150 min/week moderate,Slower CAC progression
Exercise Resistance,2-3x/week,Improved insulin sensitivity
Stress Management,Daily meditation/yoga,Reduced inflammation (hs-CRP)
Sleep Optimization,7-9 hours/night,Cardiovascular recovery

# Red Flags - Urgent Cardiology Referral Criteria
# criterion,threshold,urgency_level

CAC Score,>1000,High
CAD-RADS,4B or 5,Urgent
HRP Features,≥3 features,High
CAC Progression,>30%/year,High
Symptomatic + CCTA,CAD-RADS ≥3,Urgent
LM Stenosis,>50%,Urgent
3-Vessel Disease,≥70% stenosis,Urgent
FFR-CT Positive,<0.80,High

# Test Selection Guidelines
# clinical_scenario,recommended_test,approximate_cost_usd,radiation_msv

Asymptomatic intermediate risk,CAC Score,$100-300,1-3
Symptomatic stable chest pain,CCTA,$500-1500,3-10
High risk + family history,CAC + CCTA,$600-1800,4-13
Diabetes screening,CAC Score,$100-300,1-3
Statin decision uncertain,CAC Score,$100-300,1-3
Known CAD surveillance,CCTA,$500-1500,3-10
Post-stent evaluation,CCTA with contrast,$500-1500,3-10

# ApoB Optimal Targets by Risk Category
# risk_category,apob_target_mgdl,ldlc_equivalent_mgdl

Very High Risk (CAC >400),<50,<55
High Risk (CAC 100-400),<65,<70
Moderate Risk (CAC 1-99),<80,<100
Low Risk (CAC 0),<100,<130

# Lp(a) Risk Thresholds
# lpa_mgdl,lpa_nmol,risk_category,special_considerations

<30,<75,Low,Standard prevention
30-49,75-125,Borderline,Monitor closely
50-99,125-250,Elevated,Aggressive LDL lowering
100-150,250-375,High,Consider PCSK9i if CAC+
>150,>375,Very High,Future RNA therapy candidate

# Evidence Quality Ratings
# exam_type,evidence_quality,guideline_class,recommendation_strength

CAC Score,High (Level A),Class IIa,Moderate-Strong
CCTA CAD-RADS,High (Level A),Class I,Strong
HRP Features,Moderate-High (Level B),Class IIb,Moderate
ApoB,High (Level A),Class IIa,Moderate-Strong
Lp(a),High (Level A),Class IIa,Moderate-Strong
Vitamin K2,Moderate (Level B),N/A,Emerging
Mediterranean Diet,High (Level A),Class I,Strong
